CLAIMS

20

- 1. A hydrogel for use in the treatment or prevention of arthritis said hydrogel obtainable by combining acrylamide and methylene bis-acrylamide in amounts so as to give about 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel; radical initiation; and washing with pyrogen-free water or saline solution.
- 2. The hydrogel according to claim 1, wherein said combining acrylamide and methylene bis-acrylamide is in a molar ratio of 150:1 to 1000:1.
- The hydrogel according to claim 1, comprising less than 15% by weight polyacrylamide, based on the total weight of the hydrogel, preferably less 10%, more preferably less than 7.5%, even more preferably less than 5%, most preferably less than 3.5% by weight polyacrylamide, based on the total weight of the hydrogel.
 - 4. The hydrogel according to claim 3 comprising at least 1% by weight polyacrylamide, based on the total weight of the hydrogel, preferably at least 1.5%, such as 1.6% by weight polyacrylamide, based on the total weight of the hydrogel.
 - 5. The hydrogel according to claim 1 further comprising at least 75% by weight pyrogen-free water or saline solution, preferably pyrogen-free water.
- The hydrogel according to claim 7 comprising at least 80% by weight pyrogen-free
 water or saline solution, preferably at least 85%, more preferably at least 90%, even more preferably at least 95% by weight pyrogen-free water or saline solution.
 - 7. The hydrogel according to claim 1 having a complex viscosity of 2 to 25 Pa s, such as about 3 to 20 Pa s, preferably about 3 to 18 Pa s, most preferably about 3 to 15 Pa s.
 - 8. The hydrogel according to claim 1 having a complex viscosity less than 25 Pa s and an elasticity modulus less than 200 Pa, preferably having a complex viscosity less than 15 Pa s and an elasticity modulus less than 100 Pa.

- 9. Use of a hydrogel comprising about 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel, for the preparation of an endoprosthesis for alleviation or prevention of symptoms associated with arthritis.
- 5 10. The use according to claim 9, wherein the hydrogel comprises less than 15% by weight polyacrylamide, based on the total weight of the hydrogel, preferably less 10%, more preferably less than 7.5%, even more preferably less than 5%, most preferably less than 3.5% by weight polyacrylamide, based on the total weight of the hydrogel.
- 10 11. The use according to claim 10, wherein the hydrogel comprises at least 1% by weight polyacrylamide, based on the total weight of the hydrogel, preferably at least 1.5%, such as 1.6% by weight polyacrylamide, based on the total weight of the hydrogel.
- 12. The use according to claim 9, wherein the hydrogel has a complex viscosity of about 2 to 25 Pa s, such as about 3 to 20 Pa s, preferably about 3 to 18 Pa s, most preferably about 3 to 15 Pa s.
 - 13. The use according to claim 12, wherein the hydrogel further comprises at least 75% by weight pyrogen-free water or saline solution, preferably pyrogen-free water.
 - 14. The use according to claim 12, wherein the hydrogel comprises at least 80% by weight pyrogen-free water or saline solution, preferably at least 85 %, more preferably at least 90%, even more preferably at least 95% by weight pyrogen-free water or saline solution.
 - 15. The use according to claim 9, wherein the endoprosthesis is injected into the intraarticular cavity of a joint.
- 16. The use according to claim 9, wherein the hydrogel comprises at least 90% by weight30 pyrogen-free water or saline solution.
 - 17. A method of treating or preventing arthritis comprising administering a hydrogel to a mammal said hydrogel comprising 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel.

35

20

- 18. The method according to claim 17, wherein the hydrogel is obtainable by combining acrylamide and methylene bis-acrylamide in a molar ratio of 150:1 to 1000:1.
- 19. The method according to claim 17, wherein the hydrogel comprises less than 15% by weight polyacrylamide, based on the total weight of the hydrogel, preferably less 10%, more preferably less than 7.5%, even more preferably less than 5%, most preferably less than 3.5% by weight polyacrylamide, based on the total weight of the hydrogel.
- 20. The method according to claim 19, wherein the hydrogel comprises at least 1% byweight polyacrylamide, based on the total weight of the hydrogel, preferably at least 1.5%, such as 1.6% by weight polyacrylamide, based on the total weight of the hydrogel.
- 21. The method according to claim 17, wherein the hydrogel has a complex viscosity of about 2 to 25 Pa s, such as about 3 to 20 Pa s, preferably about 3 to 18 Pa s, mostpreferably about 3 to 15 Pa s.
 - 22. The method according to claim 17, wherein the hydrogel further comprises at least 75% by weight pyrogen-free water or saline solution, preferably pyrogen-free water.
- 20 23. The method according to claim 22, wherein the hydrogel comprises at least 80% by weight pyrogen-free water or saline solution, preferably at least 85 %, more preferably at least 90%, even more preferably at least 95% by weight pyrogen-free water or saline solution.
- 25 24. The method according to claim 17, wherein the administering comprises injecting the hydrogel into the intra-articular cavity of a joint.
 - 25. The method according to claim 17, wherein the hydrogel is radio-labelled and the administering may be monitored by visualisation.
 - 26. The method according to claim 17, comprising further injections to excessively stressed areas of the cavity.

- 27. A prosthetic device for the treatment of arthritis, wherein the device comprises a polyacrylamide hydrogel comprising 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel, said device administered to the intra-articular cavity of joint.
- 5 28. The prosthetic device according to claim 27, wherein the hydrogel further comprises at -. least 75% by weight pyrogen-free water or saline solution, preferably pyrogen-free water.
- 29. A prosthetic device for augmenting or replacing cartilage in the intra-articular cavity of a joint, said device comprising a polyacrylamide hydrogel comprising 0.5 to 25% by
 weight polyacrylamide, based on the total weight of the hydrogel.
 - 30. The prosthetic device according to claim 29, wherein the hydrogel further comprises at least 75% by weight pyrogen-free water or saline solution, preferably pyrogen-free water.
- 15 31. The prosthetic device according to claim 27, implanted or injected into the intraarticular cavity of a joint, preferably injected.

- 32. The prosthetic device according to claim 27, wherein the device is implanted and surface treated.
- 33. The prosthetic device according to claim 27, wherein the joint is selected from the group consisting of a knee joint; a hip joint; and the metacarpal-phalangeal and interphalangeal joints in hands and feet.
- 25 34. The prosthetic device according to claim 27, wherein the hydrogel is radio-labelled.
 - 35. The prosthetic device according to claim 28, wherein the joint comprises a knee joint, a hip joint, or the metacarpal-phalangeal or interphalangeal joints in hands and feet.